6th February, 2021
The World Health Organisation-led COVAX global initiative has failed to shortlist Nigeria for the Pfizer vaccines.
This is following the country’s inability to meet the standard requirement of being able to store the vaccines at the required -70 degrees Celsius.
The Nigerian government had stated that it was expected to receive 100,000 doses through the COVAX initiative, which was set up to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level.
Dr Matshidiso Moeti, the Director, WHO, African Region, while speaking at a virtual press conference said only four African countries were shortlisted for the Pfizer vaccine out of the 13 that applied.
According to Moeti, WHO could not risk the Pfizer vaccines being wasted.
She said, “Around 320,000 doses of the Pfizer-BioNTech vaccine have been allocated to four African countries – Cape Verde, Rwanda, South Africa and Tunisia. This vaccine has received WHO Emergency Use Listing but requires countries to be able to store and distribute doses at minus 70 degrees Celsius.
“To access an initial limited volume of Pfizer vaccine, countries were invited to submit proposals. Thirteen African countries submitted proposals and were evaluated by a multi-agency committee based on current mortality rates, new cases and trends, and the capacity to handle the ultra-cold chain needs of the vaccine.
“This announcement allows countries to fine-tune their planning for COVID-19 immunisation campaigns. We urge African nations to ramp up readiness and finalise their national vaccine deployment plans. Regulatory processes, cold chain systems and distribution plans need to be in place to ensure vaccines are safely expedited from ports of entry to delivery. We can’t afford to waste a single dose.”
Meanwhile, Prof Babatunde Salako, the Director-General of the Nigerian Institute of Medical Research, had said that there is not enough space at the moment to store the vaccines at that temperature.
But Dr Faisal Shuaib, the Executive Director of the National Primary Health Care Development Agency, had described the report as fake, saying Nigeria had the capacity to store the vaccines and had taken journalists on a tour of its facility in Abuja.
Nigeria was expected to be on the list of African countries to receive the first set of Pfizer vaccines because of its rate of infection which is now the sixth-highest on the continent.
Unlike the other vaccines in the market, the BioNTech/Pfizer vaccine, which has the highest WHO rating, is expected to be stored at 70 degrees Celsius which Nigeria could not meet.
However, the WHO regional director said countries that failed to make the Pfizer list could get the Oxford-AstraZeneca vaccine later in the month, although it has not yet been endorsed by the health organisation.
Moeti said, “Nearly 90 million of the Oxford/AstraZeneca vaccine could start arriving on the continent later this month. This is subject to the WHO listing the vaccine for emergency use. The review is ongoing and its outcome is expected very soon.”
The WHO director said it was time for African countries to up their game in the rollout of vaccines.
She said the initial phase of 90 million doses of COVID-19 vaccines would support countries to immunise three per cent of the African population most in need of protection, including health workers and other vulnerable groups in the first half of 2021.
“As production capacity increases and more vaccines become available, the aim is to vaccinate at least 20 per cent of Africans by providing up to 600 million doses by the end of 2021,” Moeti said.
To complement COVAX efforts, the African Union has secured 670 million vaccine doses for the continent which will be distributed in 2021 and 2022 as countries secure adequate financing.
The African Export-Import Bank will facilitate payments by providing advance procurement commitment guarantees of up to $2bn to the manufacturers on behalf of countries.